CATALOGO DEI PRODOTTI DELLA RICERCA

FATTOVICH, Giovanna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.105
EU - Europa 12.845
AS - Asia 9.311
SA - Sud America 1.130
AF - Africa 105
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 10
Totale 37.518
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.976
SG - Singapore 4.535
RU - Federazione Russa 4.270
GB - Regno Unito 3.700
CN - Cina 2.945
FR - Francia 1.088
BR - Brasile 947
DE - Germania 856
IE - Irlanda 781
SE - Svezia 704
HK - Hong Kong 636
FI - Finlandia 526
IT - Italia 516
KR - Corea 385
VN - Vietnam 354
UA - Ucraina 172
TR - Turchia 95
CA - Canada 72
AR - Argentina 66
IN - India 62
BD - Bangladesh 50
PL - Polonia 43
JP - Giappone 42
ID - Indonesia 31
ES - Italia 30
AT - Austria 29
MX - Messico 29
EC - Ecuador 26
ZA - Sudafrica 26
BE - Belgio 23
IQ - Iraq 23
NL - Olanda 21
VE - Venezuela 21
TN - Tunisia 20
CO - Colombia 17
PE - Perù 17
UZ - Uzbekistan 17
AE - Emirati Arabi Uniti 16
PK - Pakistan 16
CL - Cile 14
AZ - Azerbaigian 13
MA - Marocco 13
LT - Lituania 12
PY - Paraguay 11
KE - Kenya 10
EG - Egitto 9
EU - Europa 9
IL - Israele 9
JO - Giordania 9
PS - Palestinian Territory 9
UY - Uruguay 9
DZ - Algeria 8
SA - Arabia Saudita 8
AU - Australia 7
BG - Bulgaria 7
KG - Kirghizistan 7
AL - Albania 6
CZ - Repubblica Ceca 6
GA - Gabon 6
PT - Portogallo 6
RO - Romania 6
SN - Senegal 6
CH - Svizzera 5
GR - Grecia 5
HU - Ungheria 5
MD - Moldavia 5
NP - Nepal 5
PA - Panama 5
DO - Repubblica Dominicana 4
GE - Georgia 4
HN - Honduras 4
IR - Iran 4
LV - Lettonia 4
NO - Norvegia 4
OM - Oman 4
RS - Serbia 4
TH - Thailandia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BH - Bahrain 3
CR - Costa Rica 3
ET - Etiopia 3
JM - Giamaica 3
KZ - Kazakistan 3
LB - Libano 3
NZ - Nuova Zelanda 3
PH - Filippine 3
SK - Slovacchia (Repubblica Slovacca) 3
AO - Angola 2
BB - Barbados 2
BN - Brunei Darussalam 2
BO - Bolivia 2
EE - Estonia 2
HR - Croazia 2
KH - Cambogia 2
KW - Kuwait 2
MY - Malesia 2
NI - Nicaragua 2
QA - Qatar 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
Totale 37.505
Salva come PNG Salva come JPEG
Città #
Southend 2.941
Jacksonville 2.515
Singapore 2.378
Woodbridge 1.526
Chandler 1.414
Moscow 1.250
Ashburn 987
Ann Arbor 934
Dallas 930
Houston 832
Dublin 781
Hong Kong 631
Wilmington 418
Lawrence 372
Princeton 371
Lancaster 356
The Dalles 320
Nanjing 303
Jinan 274
Beijing 263
Sindelfingen 262
Shenyang 221
Los Angeles 217
New York 205
Buffalo 180
Kent 149
Hebei 145
Ho Chi Minh City 135
Tianjin 125
Changsha 121
Zhengzhou 105
Boardman 97
Haikou 91
Nanchang 90
Milan 87
Hanoi 80
Helsinki 78
São Paulo 78
Taizhou 75
Redondo Beach 74
Verona 74
Jiaxing 73
Guangzhou 72
Columbus 71
Hangzhou 69
Ningbo 69
Taiyuan 61
Norwalk 50
Santa Clara 47
Washington 47
Seattle 45
Munich 43
Falls Church 42
Lanzhou 41
Tokyo 37
Nuremberg 34
Chicago 32
San Jose 32
Brooklyn 28
Council Bluffs 28
Philadelphia 28
San Francisco 28
Stockholm 28
Rio de Janeiro 27
Warsaw 27
Seoul 23
Fuzhou 22
Belo Horizonte 21
Toronto 21
Boston 20
Brussels 20
Turku 19
Auburn Hills 18
Montreal 18
Falkenstein 17
Tashkent 17
Phoenix 16
Atlanta 15
Da Nang 15
Rome 15
Brasília 14
Lima 14
Porto Alegre 14
Shanghai 14
Baku 13
Dearborn 13
Dhaka 13
Fairfield 13
Haiphong 13
Johannesburg 13
Chennai 12
Elk Grove Village 12
Goiânia 12
Jakarta 12
London 12
Salvador 12
Vienna 12
Amsterdam 11
Buenos Aires 11
Frankfurt am Main 11
Totale 24.072
Salva come PNG Salva come JPEG
Nome #
Metodo radioimmunologico ed elettrosineresi nello studio dell'antigene Australia (HBAg) e dell'anticorpo (HBAc). Risultati comparativi 298
Accuracy of ultrasound in the detection of liver fibrosis in chronic viral hepatitis. 289
A 25 years longitudina study of hepatitis B e antigen positive chornic hepatitis B in italian patients 202
A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone. 188
Endogenously produced TNF-α contributes to the expression of CXCL10/IP-10 in IFN-λ3-activated plasmacytoid dendritic cells 183
A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B. 178
Protease inhibitors-based therapy induces acquired spherocytic-like anemia and ineffective erythropoiesis in chronic HCV patients 175
A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. 174
Progression to cirrhosis and mortality of chronic hepatiita type B: a cohort study with 25 years follow-up in Italy. 173
La regressione della cirrosi epatica: non più un mito. 172
The homestasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. 171
Interaction between vitamin D binding protein polymorphisms and vitamin D levels in the prediction of antiviral response in chronic hepatitis C. 171
Accuracy of VirtualTouch Acoustic Radiation Force Impulse (ARFI) Imaging for the Diagnosis of Cirrhosis during Liver Ultrasonography 170
A controlled trial of lymphoblastoid interferon for chronic anti-HBe/HBV-DNA positive hepatitis 163
Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome. 161
[Infection due to hepatitis B virus and host immune response] 160
Interleukin-28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C under real-life conditions 159
A long term study of hepatitis G virus coinfection in chronic hepatitis B 156
A multicenter prospective observational study to evaluate factors influencing efficacy, tolerance and compliance to antiviral treatment with interferon and ribavirin in daily clinical practice 156
A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. 155
Natural history of hepatitis B e antigen positive chronic hepatitis B in italian patients: a 25 years longitudinal study 154
Genetic polymorphysms of vitamin d pathway predict antiviral treatment outcome in slow responder naive patients with chronic hepatitis C 153
Hepatitis C virus genotype and prognosis of compensated cirrhosis type C 152
Effect of hepatitis B and C virus infection on the natural history of compensated cirrhosis: a cohort study of 297 patients. 152
Long-term outcome of chronic hepatitis B in caucasian patients: mortality after 25 years 152
Hepcidin suppression relative to iron status in patients with chronic Hepatitits C 152
Autoantibodies during alpha-interferon therapy for chronic hepatitis B 150
TLR4 rs4986790 A>G genetic polymorphisms predict liver fibrosis severity in Caucasian patients with chronic hepatitis C. 150
HCV gentotype 3 and circulating squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV infected patients. 150
Autonomic dysfunction and hemodynamic derangement in cirrhotic cardiomyopathy 149
A randomized study comparing 48 and 96 weeks peginterferon alfa-2a therapy in genotype D HBeAg negative chronic hepatitis B. 149
Interaction between vitamin D binding protein polymorphisms and vitamin D levels in the prediction of antiviral response in chronic hepatitis C. 149
Consensus interferon (CIFN) in combination with ribavirin (RBV) for naive patients with chronic hepatitis C: a multicenter study 147
Hepatocellularcarcinoma in cirrhosis: incidence and risk factors. 145
[Relationships between clinico-therapeutic parameters and immunological status in patients with lung cancer] 144
Malattie autoimmuni del fegato 144
A survey of clinical toxicity of alfa interferon in 11.241 patients with chronic viral hepatitis 144
A controlled trial of alpha-2 recombinant interferon for chronic HBeAg positive hepatitis 144
Influence of hepatitis delta virus infection on clinical outcome of compensated cirrhosis type B 141
Insulin resistance is not a relevant predictor of sustained virologic response in chronic hepatitis C patients: results from the Italian hepatitis C cohort study (ITAHECS) collaborative group 139
Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C 139
[Presence of HBsAg and IgG on the membrane of hepatic cells in patients with acute and chronic hepatitis] 138
A multicenter randomized double-blind placebo-controlled trial of interleukin-2 in chronic hepatitis B 138
Carriage of the EGF RS4444903 A>G functional polimorphism associates with disease progression in chronic HBV infection. 138
A controlled trial of thymopentin therapy in HBV-DNA positive chronic hepatitis B 137
Final report of a consensus interferon (CIFN) plus ribavirin (RBV) study for chronic hepatitis C (CHC) 137
Natural course and prognostic factors of hepatitis B. 136
Efficacy of prolonged high dose of interferon (IFN) plus ribavirin in young genotype 1/4 patients with chronic hepatitis C not responding to IFN alone 136
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C 136
Natural history of hepatitis B and prognostic factors of disease progression 135
Membrane oxidative damage causes hemolitic anemia during ribavirin therapy for chronic hepatitis C 134
A seven-gene signature (Cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C 134
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C 134
PEG-interferon and ribavirin in HCV-related cirrhotic patients with profound thrombocytopenia. 134
Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C. 133
Natural history of hepatitis B virus infection and disease 133
Host genetics regulates liver fibrosis progression in patients with chronic hepatitis C (CHC) 133
Efficacy and safety of consensus interferon (CIFN) plus ribavirin (RBV) for naive patients with chronic hepatitis C (CHC): final report of a pilot study 133
Natural history of chronic hepatitis B 132
Interferon (IFN) induction followed by prolonged high dose IFN in combination with ribavirin (RBV) for relapsers HCV patients: a randomized controlled multicenter trial 132
Role of membrane oxidative damage in the pathogenesis of hemolitic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection 130
Suppressor cell function in chronic active hepatitis 130
-smooth-muscle actin expression in chronic viral hepatitis before and after interferon therapy 129
Incidenza e fattori di rischio di epatocarcinoma. 127
Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily clinical parameters. 127
-smooth-muscle actin expression in chronic viral hepatitis before and after interferon therapy 126
Gestione delle infezioni da virus epatite B secondo le linee guida nazionali ed internazionali. 126
[The side effects associated with the interferon-alpha therapy of chronic viral hepatitis] 125
How to predictic the outcome of chronic hepatitis B 125
T and K cell function in acute and chronic hepatitis 125
Relationship between HBcAg in serum and liver and HBV replication in patients with HBsAg-positive chronic liver disease 124
Hepatitis C and cirrhosis 124
Serum HBV-DNA in anti-HBe positive patients detected by filter and liquid phase hybridization assays 123
Cellular immunity to the hepatitis B virion in acute and chronic infection 122
Progression to cirrhosis, hepatocellular carcinoma and liver related mortality in chronic hepatitis B patients in Italy. 122
Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis 121
Clinical and virological profiles in patients with multiple hepatitis virus infections. 121
Antifibrogenic effect of combination interferon plus ribavirin treatment in patients with chronic hepatitis C 121
Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP) 120
Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. 120
TLR4 rs4986790 A>G . genetic polymorphisms predict liver fibrosis severity in Caucasian patients with chronic hepatitis B. 120
Natural history of chronic hepatitis B virus and Hepatitis delta virus infection and disease 119
Natural history of hepatitis B 119
Heteroimmune and autoimmune reactions to liver cell surface antigens in the pathogenesis of acute and chronic hepatitis 117
Comparison of morbidity and mortality in HBsAg positive cirrhosis with or without hepatitis delta virus superinfection 117
Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage 117
Efficacy of consensus interferon (CIFN) plus ribavirin (RBV) as initial treatment for chronic hepatitis C patients: an italian multicentre study 117
Effectiveness of interferon alfa on the clinical course of caucasian patients with viral compensated cirrhosis 117
Carriage of the EGF rs4444903 A>G functional polymorphism associates with disease progression in chronic HBV infection. 117
Antibody dependent cellular cytotoxicity (ADCC) in acute hepatitis B and in chronic active hepatitis 116
Changes in serum hepatitis B virus (HBV) DNA positivity in chronic HBV infection: results of a long-term follow-up study of 138 patients 116
Virus replication and liver disease in chronic hepatitis B virus infection 116
Influence of GB virus-C/Hepatitis G Virus infection on the long term course of chronic hepatitis B 116
Interlukin-28B polymorphisms, IP-10, viral load and age predict the outcome of therapy in genotype 1 hepatitis C virus under real-life conditions 116
HLA-DR expression in liver in human HIV infection 115
Hepatitis C virus genotype and risk of hepatocellular carcinoma in compensated cirrhosis type C 115
Morbidity and mortality in compensated cirrhosis type C: relationship to interferon alpha therapy 115
Baseline serum vitamin D levels strongly predict the achievement of sustaiend viral response after antiviral therapy in patients with chronic hepatiits C 115
Natural history of HBV and HDV infection and liver disease 114
Hemolytic anemia induced by ribavirin therapy in chronic hepatitis C: role of membrane oxidative damage 113
Totale 14.131
Salva come PNG Salva come JPEG
Categoria #
all - tutte 119.238
article - articoli 51.787
book - libri 0
conference - conferenze 56.416
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 11.035
Totale 238.476
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.229 0 0 0 0 0 260 16 359 152 11 356 75
2021/20222.414 148 544 11 39 295 76 110 174 172 75 263 507
2022/20234.650 434 301 540 931 438 1.052 34 288 451 22 114 45
2023/20242.363 102 186 166 361 398 301 62 114 4 33 456 180
2024/20256.028 396 508 45 911 387 83 194 264 1.044 403 422 1.371
2025/20269.438 1.307 709 942 2.155 3.383 942 0 0 0 0 0 0
Totale 37.598